LIVRQNac (AXA1125) Enhances Insulin Sensitivity in Primary Human Hepatocytes and in Subjects With NAFLD and T2D

Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis: Results From Part A of a Randomized, Placebo-Controlled, Three-Part, Phase 3 Study

Absence of Bowel Urgency is Associated with Significantly Improved Inflammatory Bowel Disease Related Quality of Life in a Phase 2 Trial of Mirikizumabin Patients with Ulcerative Colitis

Disease burden and care-seeking behavior for IBS-C patients in the United States in the era of COVID-19

Rapid Onset of Time to First Spontaneous Bowel Movement (SBM) and Predictable Efficacy of Naloxegol: Pooled Analysis of Two Global Randomized Controlled Trials

Efficacy and Safety of Mirikizumab(LY3074828) After 12 Weeks Induction Treatment in a Phase 2 Study of Patients with Crohn’s Disease

A Single-Center Continuous Quality Improvement Program Identifies 660 Hepatitis C Infected Persons in One Year

Dupilumab Reduces Symptom Burden and Improves Health-Related Quality of Life in Patients With Eosinophilic Esophagitis: Results From Part A of a Randomized, Placebo-Controlled, Three-Part, Phase 3 Study

Efficacy of Probiotic Use and Gastroesophageal Reflux Disease Symptom Management

Safety, Tolerability, and Biological Activity of AXA1125 and AXA1957 in a Prospective 16-Week Randomized, Placebo-Controlled Study in Subjects With NAFLD With and Without Type 2 Diabetes

Mirikizumab Therapy is Associated with Improved Fatigue in Patients with Moderately to Severely Active Crohn’s Disease

Pitfalls of Physician-Directed Treatment of Helicobacter pylori Infection: Results from Two Phase 3 Clinical Trials and Real-World Prescribing Data

HCC Innovations

MirikizumabTreatment Improves Bowel Movement Urgency in Patients with Moderately to Severely Active Ulcerative Colitis

Clinical Update on the Management of Patients with Cirrhosis

Impact of Treatment With Tenofovir Alafenamide or Tenofovir Disoproxil Fumarate on Hepatocellular Carcinoma Incidence in Patients with Chronic Hepatitis B

Efficacy and Safety of MirikizumabAfter 52-Weeks Maintenance Treatment in Patients with Moderate-to-Severe Crohn’s Disease

Implementing a Hepatitis C Compliance Program